Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554

Documenti analoghi

• Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
  di: Macek Jilkova, Zuzana, et al.
  Pubblicazione: (2019)
• Comment on: Jilkova, Z.M.; et al. “Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
  di: Dunnigan, Anna
  Pubblicazione: (2020)
• Comment on: Jilkova, Z.M.; et al. “Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” <i>Cancers</i> 2019, <i>11</i>, 1554
  di: Anna Dunnigan
  Pubblicazione: (2020-09-01)
• Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
  di: Macek Jilkova, Zuzana, et al.
  Pubblicazione: (2019)
• Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
  di: Macek Jilkova, Zuzana, et al.
  Pubblicazione: (2019)